Merck (NYSE: MRK) and Gilead Sciences (NASDAQ: GILD) announced the discontinuation of their Phase 3 KEYNOTE-D46/EVOKE-03 study testing Gilead's Trodelvy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE